Bicycle Therapeutics CFO sells 923 shares for taxes

BICYCLE THERAPEUTICS PLC Chief Financial Officer Travis Alvin Thompson reported the sale of 923 Ordinary Shares in two open-market transactions.

Rhea-AI Filing Summary

BICYCLE THERAPEUTICS PLC Chief Financial Officer Travis Alvin Thompson reported the sale of 923 Ordinary Shares in two open-market transactions. The shares were sold at weighted average prices around $4.27 and $4.31 to cover statutory tax withholding obligations on vested RSUs, as required by his award agreement. Following these mandated sell-to-cover transactions, he holds 64,441 Ordinary Shares directly.

Insider Trade Summary

Net Seller: 923 shares

Net Sell 2 txns

Insider Thompson Travis Alvin

Role Chief Financial Officer

Sold 923 shs ($4K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	104	$4.31	$448.24
Sale	Ordinary Shares	819	$4.27	$3K

Holdings After Transaction: Ordinary Shares — 64,441 shares (Direct)

Footnotes (3)

1. F1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive.

Key Figures

Shares sold: 923 shares First sale price range: $4.26–$4.29 per share Second sale price range: $4.30–$4.31 per share +3 more

6 metrics

Shares sold 923 shares Total Ordinary Shares sold across two transactions

First sale price range $4.26–$4.29 per share Price range for one group of Ordinary Shares sold

Second sale price range $4.30–$4.31 per share Price range for another group of Ordinary Shares sold

Shares held after transactions 64,441 shares Direct Ordinary Share holdings following reported sales

Weighted average price (819 shares) $4.27 per share Reported weighted average for 819-share sale

Weighted average price (104 shares) $4.31 per share Reported weighted average for 104-share sale

Key Terms

RSUs, statutory tax withholding obligations, sell to cover, weighted average price

4 terms

RSUs financial

"in connection with the vesting and settlement of the RSUs."

RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.

statutory tax withholding obligations financial

"to cover the statutory tax withholding obligations in connection with the vesting"

sell to cover financial

"funded by a "sell to cover" transaction and does not represent a discretionary sale"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Bicycle Therapeutics (BCYC) CFO report in this Form 4?

The CFO reported selling 923 Ordinary Shares of Bicycle Therapeutics in two open-market transactions. These sales were linked to statutory tax withholding obligations triggered by the vesting and settlement of restricted stock units (RSUs) under his compensation award agreement.

Why did the Bicycle Therapeutics (BCYC) CFO sell 923 shares?

The 923 shares were sold to cover statutory tax withholding obligations from RSU vesting. His award agreement mandates a “sell to cover” transaction to fund minimum tax withholdings, meaning these were not discretionary sales chosen independently by the executive.

At what prices were the Bicycle Therapeutics (BCYC) CFO’s shares sold?

The reported prices are weighted averages from multiple trades. One group of shares sold between $4.26 and $4.29 per share, and another group sold between $4.30 and $4.31 per share, resulting in the disclosed weighted average sale prices.

How many Bicycle Therapeutics (BCYC) shares does the CFO hold after these sales?

After the sell-to-cover transactions, the CFO directly holds 64,441 Ordinary Shares of Bicycle Therapeutics. This post-transaction figure reflects his remaining equity position following the small number of shares sold to satisfy tax withholding requirements on recently vested RSUs.

Were the Bicycle Therapeutics (BCYC) CFO’s share sales discretionary?

The filing states the sales were mandated by the CFO’s award agreement as a “sell to cover” for statutory tax withholding. It explicitly notes these transactions do not represent discretionary sales initiated by the reporting person for portfolio or timing reasons.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Travis Alvin

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE CB21 6GS

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	07/02/2026		S(1)		819	D	$4.27(2)	64,545	D
Ordinary Shares	07/06/2026		S(1)		104	D	$4.31(3)	64,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary sale by the Reporting Person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.26 to $4.29 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.30 to $4.31 inclusive.

	/s/ Travis Thompson	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)